Immix Biopharma Analyst Ratings
Immix Biopharma Analyst Ratings
While ratings are subjective and will change, the latest Immix Biopharma (IMMX) rating was a reiterated with a price target of $0.00 to $14.00. The current price Immix Biopharma (IMMX) is trading at is $1.84, which is within the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/14/2023 | 660.91% | Roth MKM | → $14 | Reiterates | Buy → Buy |
| 02/22/2023 | 660.91% | Roth MKM | → $14 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 08/14/2023 | 660.91% | Roth MKM | → 14 美元 | 重申 | 购买 → 购买 |
| 02/22/2023 | 660.91% | Roth MKM | → 14 美元 | 启动覆盖开启 | → 购买 |
What is the target price for Immix Biopharma (IMMX)?
Immix Biopharma（IMMX）的目标价格是多少？
The latest price target for Immix Biopharma (NASDAQ: IMMX) was reported by Roth MKM on August 14, 2023. The analyst firm set a price target for $14.00 expecting IMMX to rise to within 12 months (a possible 660.91% upside). 2 analyst firms have reported ratings in the last year.
Roth MKM于2023年8月14日公布了Immix Biopharma（纳斯达克股票代码：IMMX）的最新目标股价。这家分析公司将目标股价定为14.00美元，预计IMMX将在12个月内升至12个月内（可能上涨660.91％）。去年有2家分析公司公布了评级。
What is the most recent analyst rating for Immix Biopharma (IMMX)?
分析师对Immix Biopharma（IMMX）的最新评级是多少？
The latest analyst rating for Immix Biopharma (NASDAQ: IMMX) was provided by Roth MKM, and Immix Biopharma reiterated their buy rating.
Immix Biopharma（纳斯达克股票代码：IMMX）的最新分析师评级由Roth MKM提供，Immix Biopharma重申了他们的买入评级。
When is the next analyst rating going to be posted or updated for Immix Biopharma (IMMX)?
Immix Biopharma（IMMX）的下一个分析师评级何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Immix Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Immix Biopharma was filed on August 14, 2023 so you should expect the next rating to be made available sometime around August 14, 2024.
分析师在进行了广泛的研究（包括浏览公开财务报表、与Immix Biopharma的高管和客户交谈以及听取财报电话会议）后得出了股票评级。大多数分析师每三个月进行一次评级，因此每家公司每年应该获得4个评级。Immix Biopharma的最后一次评级是在2023年8月14日提交的，因此您应该预计下一个评级将在2024年8月14日左右公布。
Is the Analyst Rating Immix Biopharma (IMMX) correct?
分析师对Immix Biopharma（IMMX）的评级正确吗？
While ratings are subjective and will change, the latest Immix Biopharma (IMMX) rating was a reiterated with a price target of $0.00 to $14.00. The current price Immix Biopharma (IMMX) is trading at is $1.84, which is within the analyst's predicted range.
尽管评级是主观的，将会发生变化，但最新的Immix Biopharma（IMMX）评级得到了重申，目标股价为0.00美元至14.00美元。Immix Biopharma（IMMX）目前的交易价格为1.84美元，在分析师的预测区间内。
